What are the recommendations for the use of RAS inhibitors in CKD G1-G4?
The recommendations presented in this section governing initiation of RASi apply only to CKD G1-G4 since there is currently no RCT evidence on the use of these agents in CKD G5. The benefits and harms of initiation, continuation, or discontinuation of RASi in CKD G5 have not been tested in RCTs. The evidence review included an assessment of subgroups based on the amount of albuminuria (A1 [ACR <30 mg/g or 3 mg/mmol], mg/mmol], respectively).